Protalix BioTherapeutics (FRA:PBDA) 3-Year EBITDA Growth Rate : 0.90% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics 3-Year EBITDA Growth Rate?

Protalix BioTherapeutics's EBITDA per Share for the three months ended in Dec. 2023 was €-0.06.

During the past 3 years, the average EBITDA Per Share Growth Rate was 0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Protalix BioTherapeutics was 53.40% per year. The lowest was -84.50% per year. And the median was 12.00% per year.

Competitive Comparison of Protalix BioTherapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Protalix BioTherapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protalix BioTherapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's 3-Year EBITDA Growth Rate falls into.

Protalix BioTherapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Protalix BioTherapeutics (FRA:PBDA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Protalix BioTherapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Protalix BioTherapeutics (FRA:PBDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

PLX:USA

Address

2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601

Website

https://www.protalix.com

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

Protalix BioTherapeutics (FRA:PBDA) Headlines

No Headlines